Evidence map›Paper›PMID 39570802›Full record

ArticleCancer research2025

Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-Smokers.

Yun-Ching Chen, Chia-Lang Hsu, Hui-Min Wang, Shang-Gin Wu, Yih-Leong Chang, Jin-Shing Chen, Yu-Ching Wu, Yen-Ting Lin, Ching-Yao Yang, Mong-Wei Lin and 12 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. eLife · 2025
    Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yun-Ching Chen *Interventional Oncology, Johnson & Johnson Enterprise Innovation, Inc., Boston, Massachusetts.ORCID 0009-0001-8602-0680
Chia-Lang Hsu *Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-7447-8045
Hui-Min Wang *Interventional Oncology, Johnson & Johnson Enterprise Innovation, Inc., Boston, Massachusetts.ORCID 0009-0006-3932-1604
Shang-Gin Wu *Department of Medicine, National Taiwan University Cancer Center and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0001-8889-689X
Yih-Leong ChangDepartment of Pathology, National Taiwan University Cancer Center and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0001-5309-0554
Jin-Shing ChenDepartment of Surgery Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.ORCID 0000-0001-5077-4483
Yu-Ching WuDepartment of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0002-6989-6525
Yen-Ting LinDepartment of Medicine, National Taiwan University Cancer Center and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-3350-9140
Ching-Yao YangDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0003-4927-4814
Mong-Wei LinDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0003-1268-3729
Jang-Ming LeeDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0001-9727-227X
Shuenn-Wen KuoDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0001-5026-5582
Ke-Cheng ChenDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0001-6330-0674
Hsao-Hsun HsuDepartment of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-0376-1206
Pei-Ming HuangDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.ORCID 0000-0001-5493-7673
Yen-Lin HuangDepartment of Pathology, National Taiwan University Cancer Center and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0003-1444-780X
Chong-Jen YuDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-4729-6887
Mehdi PiroozniaInterventional Oncology, Johnson & Johnson Enterprise Innovation, Inc., Boston, Massachusetts.ORCID 0000-0002-4210-6458
Bevan E HuangInterventional Oncology, Johnson & Johnson Enterprise Innovation, Inc., Boston, Massachusetts.ORCID 0000-0002-1981-5838
Rob YangInterventional Oncology, Johnson & Johnson Enterprise Innovation, Inc., Boston, Massachusetts.ORCID 0000-0002-5546-7199
Jin-Yuan ShihDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0002-2854-5067
Pan-Chyr YangDepartment of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0001-6330-6048

Funding

Ministry of Science and Technology (MOST) MOST 109-3111-8-002-001
6 · The paper itself

Abstract

Lung cancer is the most common cause of cancer mortality globally, and the prevalence of lung adenocarcinoma, the most common lung cancer subtype, has increased sharply in East Asia. Early diagnosis leads to better survival rates, but this requires an improved understanding of the molecular changes during early tumorigenesis, particularly in nonsmokers. In this study, we performed whole-exome sequencing and RNA sequencing of samples from 94 East Asian patients with precancerous lesions [25 with atypical adenomatous hyperplasia (AAH); 69 with adenocarcinoma in situ (AIS)] and 73 patients with early invasive lesions [minimally invasive adenocarcinoma (MIA)]. Cellular analysis revealed that the activities of endothelial and stromal cells could be used to categorize tumors into molecular subtypes within pathologically defined types of lesions. The subtypes were linked with the radiologically defined type of lesions and corresponded to immune cell infiltration throughout the early progression of lung adenocarcinoma. Spatial transcriptomic analysis revealed the distribution of epithelial cells, endothelial cells, fibroblasts, and plasma cells within MIA samples. Characterization of the molecular lesion subtypes identified positively selected mutational patterns and suggested that angiogenesis in the late-stage AIS type potentially contributes to tissue invasion of the MIA type. This study offers a resource that may help improve early diagnosis and patient prognosis, and the findings suggest possible approaches for early disease interception. Significance: Integrative analysis of multiomics data revealed coordination between immune and nonimmune cells during early progression of precancerous lesions to lung adenocarcinomas and shed light on the molecular characteristics of clinically defined subtypes.

Indexed as

Adenocarcinoma of LungBiomarkers, TumorLung NeoplasmsPrecancerous ConditionsAdenocarcinoma in SituAgedDisease ProgressionExome SequencingFemaleGene Expression ProfilingHumansMaleMiddle AgedMultiomicsMutationPrognosisBiomarkers, Tumor

Identifiers

PMID39570802
PMCPMC11786955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.